Fexofenadine As Adjuvant Therapy in Parkinson Disease

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 10, 2026

Study Completion Date

December 20, 2026

Conditions
Parkinson Disease
Interventions
DRUG

Levodopa/carbidopa

A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD

DRUG

Fexofenadine

Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines

Trial Locations (1)

31511

RECRUITING

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER